Algernon Pharmaceuticals Inc (AGNPF)

[tcm55]

Opinion,
It seems that the COVID-19 Ifenprodil Clinical Trial has some steep targets and outcomes as Primary and Secondary outcomes. I have seen some COVID stock drug Trials with the simplest descriptions and apparently much easier targets.
Dr. Williams seems to have expected strong results with the higher targets he set. Seems like he actually expects Results as compared to some. Was it a mistake to set Ifenprodil high goals OR will serious considerations be given by the DSMB and FDA for Actual significant results?

Ifenprodil CT with actual Real world designated targets"
https://clinicaltrials.gov/ct2/show/NCT04382924?term=Ifenprodil&cond=COVID&draw=2&rank=1




Another Trial
" Primary Outcome Measures :
Efficacy: Frequency of hospitalization or death [ Time Frame: From time of first dose through Day 28 following randomization ]
Proportion of patients meeting a composite endpoint of hospitalization or death


Secondary Outcome Measures :
Safety: Changes in adverse events from baseline to end of study [ Time Frame: From time of first dose through Day 28 following randomization ]
Number of adverse events


WTF?
...GLTA...